

Hit List

[Clear](#)[Generate Collection](#)[Print](#)[Fwd Refs](#)[Bkwd Refs](#)[Generate OACS](#)

Search Results - Record(s) 1 through 6 of 6 returned.

☐ 1. Document ID: US 20040029228 A1

Using default format because multiple data bases are involved.

L2: Entry 1 of 6

File: PGPB

Feb 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040029228
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040029228 A1

TITLE: Cytokine receptor

PUBLICATION-DATE: February 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Presnell, Scott R.	Tacoma	WA	US	
Xu, Wenfeng	Seattle	WA	US	
Novak, Julia E.	Suquamish	WA	US	
Whitmore, Theodore E.	Redmond	WA	US	
Grant, Francis J.	Seattle	WA	US	
Kindsvogel, Wayne R.	Seattle	WA	US	
Klucher, Kevin M.	Bellevue	WA	US	

US-CL-CURRENT: [435/69.1](#); [435/320.1](#), [435/325](#), [530/350](#), [536/23.5](#)

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 2. Document ID: US 20030224487 A1

L2: Entry 2 of 6

File: PGPB

Dec 4, 2003

PGPUB-DOCUMENT-NUMBER: 20030224487
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030224487 A1

TITLE: Novel cytokine zcytor17 ligand

PUBLICATION-DATE: December 4, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sprecher, Cindy A.	Sierra Vista	AZ	US	
Kuijper, Joseph L.	Kenmore	WA	US	
Dasovich, Maria M.	Seattle	WA	US	
Grant, Francis J.	Seattle	WA	US	
Hammond, Angela K.	Kirkland	WA	US	
Novak, Julia E.	Suquamish	WA	US	

Gross, Jane A.	Seattle	WA	US
Dillon, Stacey R.	Seattle	WA	US

US-CL-CURRENT: 435/69.5; 435/320.1, 435/325, 435/70.21, 530/351, 530/388.23, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 3. Document ID: US 20030104416 A1

L2: Entry 3 of 6

File: PGPB

Jun 5, 2003

PGPUB-DOCUMENT-NUMBER: 20030104416
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030104416 A1

TITLE: Cytokine protein family

PUBLICATION-DATE: June 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Sheppard, Paul O.	Granite Falls	WA	US	
Fox, Brian A.	Seattle	WA	US	
Klucher, Kevin M.	Bellevue	WA	US	
Taft, David W.	Kirkland	WA	US	
Kindsvogel, Wayne	Seattle	WA	US	

US-CL-CURRENT: 435/6

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

☐ 4. Document ID: US 20030027253 A1

L2: Entry 4 of 6

File: PGPB

Feb 6, 2003

PGPUB-DOCUMENT-NUMBER: 20030027253
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030027253 A1

TITLE: Cytokine receptor zcytor19

PUBLICATION-DATE: February 6, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Presnell, Scott R.	Tacoma	WA	US	
Xu, Wenfeng	Mukilteo	WA	US	
Novak, Julia E.	Bainbridge Island	WA	US	
Whitmore, Theodore E.	Redmond	WA	US	
Grant, Francis J.	Seattle	WA	US	

US-CL-CURRENT: 435/69.1; 435/320.1, 435/325, 435/6, 530/350, 536/23.5

Full	Title	Citation	Front	Review	Classification	Date	Reference	Sequences	Attachments	Claims	KMC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	-----------	-------------	--------	-----	-----------	-------

DERWENT-ACC-NO: 2003-854110

DERWENT-WEEK: 200412

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: New Zcytor19 receptor polypeptides and polynucleotides, useful for detecting and treating viral infections, cancer or autoimmune diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes or glomerulonephritis)

INVENTOR: GRANT, F J; KINDSVOGEL, W R ; KLUCHER, K M ; NOVAK, J E ; PRESNELL, S R ; WHITMORE, T E ; XU, W

PRIORITY-DATA: 2002US-373813P (April 19, 2002), 2003US-0420034 (April 18, 2003)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
US <u>20040029228 A1</u>	February 12, 2004		000	C07K014/705
WO <u>2003089603 A2</u>	October 30, 2003	E	186	C12N000/00

INT-CL (IPC): C07 H 21/04; C07 K 14/705; C12 N 0/00; C12 N 5/06; C12 P 21/02

ABSTRACTED-PUB-NO: WO2003089603A

BASIC-ABSTRACT:

NOVELTY - An isolated polynucleotide that encodes a soluble receptor polypeptide, is new. The encoded polypeptide comprises:

(a) a sequence of 211 amino acids (S1) fully defined in the specification, from amino acid residues 21-163, 1-163, 21-211 or 1-211; or

(b) a sequence at least 90% identical to (a).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) an expression vector comprising the following operably linked elements:

(a) a transcription promoter;

(b) a first DNA segment encoding the soluble receptor polypeptide;

(c) a transcription terminator;

(d) a second transcription promoter;

(e) a second DNA segment encoding a soluble CRF2-4 polypeptide; and

(f) a second transcription terminator, where the first and second DNA segments are contained within a single expression vector or are contained within independent expression vectors;

(2) a cultured cell comprising the above expression vector, where the cell expresses the polypeptides encoded by the DNA segments, and where the first and second DNA segments are located on independent expression vectors and are co-transfected into the cell;

(3) an isolated polypeptide encoded by the above polynucleotide;

(4) producing (M1) polypeptides that form a heterodimer, comprising culturing the cell cited above and isolating the polypeptides produced by the cell;

(5) producing (M2) an antibody to a polypeptide, comprising inoculating an animal with the above polypeptide, where the polypeptide elicits an immune response in the animal to produce

the antibody, and isolating the antibody from the animal; and

(6) an antibody produced by M2 which specifically binds to a heterodimeric receptor complex.

ACTIVITY - Virucide; Cytostatic; Immunosuppressive; Antirheumatic; Antiarthritic; Neuroprotective; Antidiabetic; Nephrotropic; Antiinflammatory; Gastrointestinal-Gen.

No biological data given.

MECHANISM OF ACTION - Soluble Zcytor19 receptor blocking ligand binding to the cellular receptor.

USE - The composition and methods are useful in detecting and treating viral infections, cancer or autoimmune diseases (e.g. rheumatoid arthritis, multiple sclerosis, diabetes, glomerulonephritis or inflammatory bowel diseases) in vitro and in vivo. The ligand-binding receptor polypeptides may also be used in blocking ligand activity in vitro and in vivo.

Full	Title	Citation	Front	Review	Classification	Date	Reference			Claims	KWC	Draw Desc	Image
------	-------	----------	-------	--------	----------------	------	-----------	--	--	--------	-----	-----------	-------

☐ 6. Document ID: EP 1356046 A2, WO 200244209 A2, AU 200241533 A, US 20030027253 A1

L2: Entry 6 of 6

File: DWPI

Oct 29, 2003

DERWENT-ACC-NO: 2002-527700

DERWENT-WEEK: 200379

COPYRIGHT 2004 DERWENT INFORMATION LTD

TITLE: Novel Zcytor19 polypeptides and polynucleotides useful for stimulating immune responses in animals for producing antibodies, and for treating autoimmune diseases, leukemia and asthma

INVENTOR: GRANT, F J; NOVAK, J E ; PRESNELL, S R ; WHITMORE, T E ; XU, W

PRIORITY-DATA: 2001US-267211P (February 7, 2001), 2000US-253561P (November 28, 2000), 2001US-0995898 (November 28, 2001)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
<u>EP 1356046 A2</u>	October 29, 2003	E	000	C12N015/12
<u>WO 200244209 A2</u>	June 6, 2002	E	200	C07K014/705
<u>AU 200241533 A</u>	June 11, 2002		000	C07K014/705
<u>US 20030027253 A1</u>	February 6, 2003		000	C12Q001/68

INT-CL (IPC): C07 H 21/04; C07 K 14/705; C07 K 14/715; C07 K 16/28; C12 N 1/21; C12 N 5/06; C12 N 5/10; C12 N 15/12; C12 N 15/62; C12 P 21/02; C12 Q 1/68; G01 N 33/68

ABSTRACTED-PUB-NO: WO 200244209A

BASIC-ABSTRACT:

NOVELTY - An isolated Zcytor19 polypeptide (I) comprising amino acids (a.as) 21(R)-223(P), 21(R)-226(N), 21(R)-249(W), 250(K)-491(R), 21(R)-491(R) or 1(M)-491(R) of a sequence (S1) comprising 491 a.as, a.as 250(K)-520(R), 21(R)-520(R) or 1(M)-520(R) of a sequence (S2) comprising 520 a.as, or a.as 21(R)-163(W), 21(R)-211(S) or 1(M)-211(S) of a sequence (S3) comprising 211 a.as, fully defined in the specification, is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) a polynucleotide (IIa) encoding (I);

(2) a DNA construct (IIb) encoding a fusion protein, comprising a first segment encoding (I) and at least one other DNA segment encoding an additional polypeptide, where the first and the other DNA segments are connected in-frame, and they together encode the fusion protein;

(3) an expression vector (III) comprising a transcription promoter, (IIa) or (IIb), and a transcription terminator, where the promoter is operably linked to (IIa) or (IIb), and (IIa) or (IIb) is operably linked to the transcription terminator;

(4) a cultured cell (IV) comprising (III), where the cell expresses a polypeptide encoded by the DNA segment or DNA construct;

(5) producing a fusion protein, by culturing (IV) and isolating the polypeptide produced by the cell;

(6) producing (I);

(7) an isolated polypeptide comprising an amino acid segment, comprising amino acids 21(R)-226 (N) of S1, 21(R)-211(S) of S3, a sequence (S4) comprising 203 amino acids fully defined in the specification, or a sequence having at least 90% identity to the above said sequences, where the polypeptide is substantially free of transmembrane and extracellular domains ordinarily associated with hematopoietic receptors;

(8) producing an antibody to a polypeptide;

(9) an antibody (Ab) produced by the above said method, which specifically binds to S1, S2 or S3, or which binds specifically to (I);

(10) detecting a cytokine receptor ligand within a test sample;

(11) detecting a genetic abnormality in a patient; and

(12) detecting a cancer in a patient.

ACTIVITY - Immunosuppressive; cytostatic; antirheumatic; antiarthritic; neuroprotective; antidiabetic; antiinflammatory; nephrotropic; dermatological; anti-HIV; hemostatic.

MECHANISM OF ACTION - Modulator of cytokine receptor protein; vaccine (claimed).

No supporting data given.

USE - (IV) Is useful for detecting the presence of a modulator of the activity of a cytokine receptor protein. Ab Is useful for detecting cancer in a patient (claimed).

(I) Or Ab is useful for suppressing immune system for reducing rejection of tissue or organ transplants and grafts and for treating T-cell specific leukemias or lymphomas and autoimmune diseases including rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory bowel disease and Crohn's disease. Ab Is useful for treating immunologic renal diseases, glomerulonephritis, mesangioproliferative disease, chronic lymphocytic leukemia, secondary glomerulonephritis or vasculitis associated with lupus, polyarteritis, scleroderma, HIV-related diseases, amyloidosis and hemolytic uremic syndrome. (I) and Ab is useful for renal or urological neoplasms and multiple myelomas, asthma, bronchitis, emphysema and other chronic airway diseases.

Ab Is also useful as vaccines. (I) Is useful for raising Ab and for identifying modulators of (I). (I) Is also useful as an aid to teach preparation of antibodies, identifying proteins by Western blotting, protein purification, determining the weight of expressed Zcytor19 polypeptides as a ratio of total protein expressed, identifying peptide cleavage sites, coupling amino and carboxyl terminal tags, amino acid sequence analysis, for teaching analytical skills, and for monitoring biological activities of both the native and tagged protein in vitro and in vivo. Ab Is also useful as a teaching aid to prepare affinity chromatography columns to purify Zcytor19, cloning and sequencing the polynucleotide encoding Ab, and as a practicum for teaching humanized antibody design. Ab Is useful for screening biological samples in vitro for the presence of Zcytor19, and for isolating DNA sequences that encode human Zcytor19 genes from cDNA libraries. Ab Is useful for tagging cells that express zcytor19, for isolating zcytor19 by affinity purification, for diagnostic assays for determining circulating levels of zcytor19 polypeptides, for detecting or quantitating soluble zcytor19 as marker of underlying pathology or disease, for detecting or quantitating in a histologic biopsy and for stimulating cytotoxicity and for screening expression libraries.

Term	Documents
ZCYTOR19	6
ZCYTOR19S	0
ZCYTOR19.PGPB,USPT,DWPI.	6
(ZCYTOR19).PGPB,USPT,DWPI.	6

Display Format:

[Previous Page](#) [Next Page](#) [Go to Doc#](#)